- Conditions
- Presumed Ocular Histoplasmosis
- Interventions
- Faricimab Injection [Vabysmo]
- Drug
- Lead sponsor
- Cincinnati Eye Institute, Southwest Ohio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Dayton, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 131
matching trials from the live ClinicalTrials.gov search.
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
- Interventions
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Genetic · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 671 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 89
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more
- Conditions
- Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
- Interventions
- ADVM-022
- Biological
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 9
- States / cities
- Bakersfield, California • Beverly Hills, California • Lakewood, Colorado + 6 more
- Conditions
- Neovascular Polypoidal Choroidal Vasculopathy
- Interventions
- Rescue Intravitreal Aflibercept Injection, Rescue Therapy with PDT, Laser or Intravitreal Steroids
- Drug · Procedure
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Polypoidal Choroidal Vasculopathy
- Interventions
- ranibizumab 0.5 or 0.3 mg/0.05 cc
- Drug
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization, Genetic Counseling
- Interventions
- Early disclosure, Late disclosure
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Choroidal Neovascularization, Age-Related Macular Degeneration
- Interventions
- Periocular injection of triamcinolone acetonide 40mg
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Portland, Oregon
- Conditions
- Age-Related Macular Degeneration
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Bakersfield, California • La Jolla, California • Santa Barbara, California + 1 more
- Conditions
- Choroidal Neovascularization, Wet Macular Degeneration
- Interventions
- ICON-1, aflibercept
- Biological
- Lead sponsor
- Iconic Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Santa Ana, California • Syracuse, New York + 5 more
- Conditions
- Choroidal Neovascularization, Macular Degeneration
- Interventions
- Fluocinolone
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Macular Degeneration
- Interventions
- Celecoxib
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Macular Degeneration
- Interventions
- Epi-Rad90™ Ophthalmic System, ranibizumab
- Device · Drug
- Lead sponsor
- NeoVista
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 18 more
- Conditions
- Choroidal Neovascularization
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Vision Research Foundation
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Not listed
- Lead sponsor
- Michael Abramoff
- Other
- Eligibility
- 45 Years to 120 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Macular Degeneration
- Interventions
- ranibizumab, verteporfin
- Drug
- Lead sponsor
- Texas Retina Associates
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 3
- States / cities
- Santa Barbara, California • Ann Arbor, Michigan • Arlington, Texas
- Conditions
- Age-Related Macular Degeneration
- Interventions
- E10030, ranibizumab, E10030 sham intravitreal injection
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 619 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- STAKEL
- Drug
- Lead sponsor
- Steba Biotech S.A.
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • West Columbia, South Carolina • Harlingen, Texas
- Conditions
- Age Related Macular Degeneration
- Interventions
- NeoVista Ophthalmic System
- Device
- Lead sponsor
- NeoVista
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Honolulu, Hawaii
- Conditions
- Central Retinal Vein Occlusion, Choroidal Neovascularization, Age-related Macular Degeneration, Branch Retinal Vein Occlusion
- Interventions
- Conj flora Antibiotic resistance
- Procedure
- Lead sponsor
- Mid Atlantic Retina
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)
- Drug
- Lead sponsor
- Light Sciences LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Interventions
- bevacizumab, ranibizumab
- Biological
- Lead sponsor
- Outlook Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 50
- States / cities
- Tucson, Arizona • Arcadia, California • Beverly Hills, California + 46 more
- Conditions
- Macular Degeneration
- Interventions
- pegaptanib sodium
- Drug
- Lead sponsor
- Eyetech Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Bridgeport, Connecticut • Hamden, Connecticut + 16 more
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Sirolimus in combination with ranibizumab, Placebo in combination with ranibizumab
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Wet Macular Degeneration
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 559 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more